Trial Profile
Real World Evidence of the Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2019
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms REACH
- Sponsors AbbVie
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 11 Sep 2017 Planned number of patients changed from 100 to 150.
- 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.